Brief Summary

The goal of this observational study is to learn about rejection in lung transplantation.

The main question it aims to answer is:

• what is the role of immune checkpoints in lung transplantation? Participants will describe pathways of rejection in lung transplantation analyzing the immune checkpoints on explanted lungs as well as trans-bronchial biopsies.

Conditions

• Lung Transplant Rejection

Intervention / Treatment

• Diagnostic Test: Immune checkpoints analysis
• Diagnostic Test: Gene expression analysis

Primary Outcome Measures

• Lung-tissue immune-checkpoint profile and bronchoalveolar immune-cells mRNA signature in acute rejection after lung transplantation. (Twelve months after lung transplantation (prospective data))
  Prevalence of immune checkpoint markers and gene-expression on leukocytes from transbronchial biopsies and bronchoalveolar lavage. Participants: cohort number 3.
• Lung-tissue immune-checkpoint profile in chronic rejection after lung transplantation. (Cohort 1: at re-transplantation for chronic lung allograft dysfunction (cross-sectional data). Cohort 2: from one to 36 months after lung transplantation (retrospective data))
  Prevalence of immune checkpoint markers on leukocytes from explanted lung grafts and transbronchial biopsies. Participants: cohort number 1 and 2.

Countries

Italy

Locations and Investigators

• Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy
  • Mario Nosotti, Medicine
  • Ilaria Righi, Medicine
  • Mario Nosotti, Medicine (Principal Investigator)
  • Ilaria Righi, Medicine
  • Lorenzo Rosso, Medicine
  • Valentina Vaira, Biology
  • Mario Clerici, Medicine
  • Daria Trabattoni, Biology
• University of Modena and Reggio Emilia, Modena, Italy
  • Marcello Pinti, Biology
• University of Padua, Padova, Italy
  • Marco Schiavon, Medicine
• University of Turin, Torino, Italy
  • Massimo Boffini, Medicine

Study Officials

• Mario Nosotti, Medicine (Principal Investigator) — University of Milan, Italy